Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment.

Pharmacogenetics - 1 Aug 2002

Rau Thomas, Heide Roland, Bergmann Klaus, Wuttke Henrike, Werner Ulrike, Feifel Nico, Eschenhagen Thomas

Abstract excerpt

The beta1 selective beta-blocker metoprolol is metabolized predominantly but not exclusively by CYP2D6. Due to the polymorphism of the CYP2D6 gene, CYP2D6 activity varies markedly between individuals. Consequently, after short-term administration metoprolol plasma concentrations were found to be several fold higher in poor metabolizers than in extensive metabolizers. However, it is currently not known, whether...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hypertension
Share to Adrenergic beta-Antagonists

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromatography, High Pressure Liquid

Share to Coronary Artery Disease

Share to Cross-Sectional Studies

Share to Cytochrome P-450 CYP2D6

Share to Drug Administration Schedule

Share to Metoprolol

Source

Identifiers

PMID: 12172215
DOI: 10.1097/00008571-200208000-00007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment.PMID 12172215Read ↗

Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.Semantic proximity Read ↗

The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients.Semantic proximity Read ↗

Cytochrome P450 2D6 phenotype and genotype in hypertensive patients on long-term therapy with metoprolol.Semantic proximity Read ↗

Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study.Semantic proximity Read ↗

Impact of genotype-predicted CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction - a prospective observational study.Semantic proximity Read ↗

Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol.Semantic proximity Read ↗

Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol.Semantic proximity Read ↗

Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.Semantic proximity Read ↗

The relationship between plasma concentration of metoprolol and CYP2D6 genotype in patients with ischemic heart disease.Semantic proximity Read ↗

Study on genotype and phenotype of novel CYP2D6 variants using pharmacokinetic and pharmacodynamic models with metoprolol as a substrate drug.Semantic proximity Read ↗

Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.Semantic proximity Read ↗

CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.